Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma

OBJECTIVE: Immune checkpoint inhibitors (ICI) can cause endocrine adverse events. However, endocrine AEs could be related to better treatment outcomes. Our aim was to investigate whether this holds true in a real-world setting of metastatic melanoma patients. DESIGN: A retrospective single-instituti...

Descripción completa

Detalles Bibliográficos
Autores principales: Karhapää, Hanna, Mäkelä, Siru, Laurén, Hanna, Jaakkola, Marjut, Schalin-Jäntti, Camilla, Hernberg, Micaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859941/
https://www.ncbi.nlm.nih.gov/pubmed/35015699
http://dx.doi.org/10.1530/EC-21-0562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859941/
https://www.ncbi.nlm.nih.gov/pubmed/35015699
http://dx.doi.org/10.1530/EC-21-0562

Ejemplares similares